- Home
- FATE vs CLLS Comparison
FATE vs CLLS Comparison
Compare FATE & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FATE
- CLLS
- Stock Information
- Founded
- FATE 2007
- CLLS 1999
- Country
- FATE United States
- CLLS France
- Employees
- FATE N/A
- CLLS N/A
- Industry
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- FATE Health Care
- CLLS Health Care
- Exchange
- FATE Nasdaq
- CLLS Nasdaq
- Market Cap
- FATE 133.0M
- CLLS 144.4M
- IPO Year
- FATE 2013
- CLLS 2007
- Fundamental
- Price
- FATE $1.21
- CLLS $1.46
- Analyst Decision
- FATE Hold
- CLLS Buy
- Analyst Count
- FATE 8
- CLLS 3
- Target Price
- FATE $4.14
- CLLS $6.67
- AVG Volume (30 Days)
- FATE 1.8M
- CLLS 48.8K
- Earning Date
- FATE 05-13-2025
- CLLS 05-12-2025
- Dividend Yield
- FATE N/A
- CLLS N/A
- EPS Growth
- FATE N/A
- CLLS N/A
- EPS
- FATE N/A
- CLLS N/A
- Revenue
- FATE $13,335,000.00
- CLLS $54,747,000.00
- Revenue This Year
- FATE N/A
- CLLS $48.52
- Revenue Next Year
- FATE N/A
- CLLS $5.17
- P/E Ratio
- FATE N/A
- CLLS N/A
- Revenue Growth
- FATE 105.85
- CLLS 351.26
- 52 Week Low
- FATE $0.66
- CLLS $1.10
- 52 Week High
- FATE $5.92
- CLLS $2.81
- Technical
- Relative Strength Index (RSI)
- FATE 53.44
- CLLS 48.19
- Support Level
- FATE $1.12
- CLLS $1.46
- Resistance Level
- FATE $1.38
- CLLS $1.60
- Average True Range (ATR)
- FATE 0.12
- CLLS 0.09
- MACD
- FATE 0.01
- CLLS -0.01
- Stochastic Oscillator
- FATE 62.22
- CLLS 39.13
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.